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ABSTRACT
Objectives: The European Transparency Directive requires
that reimbursement decisions of member states are taken in a
transparent, objective, and veriﬁable way within strict time-
lines. We investigated whether evidence of therapeutic value
was a factor affecting the Belgian pharmaceutical reimburse-
ment decision without compromising the respect of strict
timelines.
Methods: We analyzed 824 reimbursement submissions
within the period 2002 to 2004.
Results: Only 67 submissions claimed added therapeutic
value versus available alternatives: if the applicant failed to
prove added value the odds ratio (OR) for a negative decision
increased signiﬁcantly: OR = 9.1 (2.3–35.6). There were 399
“limited evidence” submissions (new medicinal products or
new indications) and 425 “extended evidence” submissions
(mainly line extensions). The OR for a negative decision
decreased signiﬁcantly for submissions with extended evi-
dence: OR = 0.18 (0.12–0.27). The median time to decision
was 175 days.
Conclusions: Both factors suggest that evidence plays a role
in the decision-making process.
Keywords: decision-making, EBM, reimbursement,
therapeutic value.
Introduction
Submissions for Market Authorization Application
for medicines for human use are regulated within the
European Union (EU) with relevant procedures at
community level in which the value of medicines is
considered in terms of efﬁcacy, safety, and pharmaceu-
tical quality [1]. Regarding reimbursement submission,
however, individual member states are competent [2].
Other major differences in procedure between sub-
missions for market authorization or reimbursement
relate to criteria for assessment (efﬁcacy and safety
vs. additional elements), hypothesis (individual drug
beneﬁt/risk ratio vs. [added] value compared to thera-
peutic alternatives), and comparator (mainly placebo
vs. active comparator).
According to the Transparency Directive [2],
however, pricing and reimbursement decisions must be
taken in a transparent, objective, and veriﬁable way
with respect of strict timelines (maximum of 180 days
from submission to decision).
Objective
The aim of this work is to analyze whether evidence of
therapeutic value of a medicinal product is affecting
the Belgian reimbursement decision, without compro-
mising the respect for the strict timelines.
Methods
The legal framework adapting the Belgian reimburse-
ment procedure to become compliant with the Euro-
pean Directive was implemented by January 1, 2002:
the reimbursement process is described in the legal text
available from the National Insurance Agency web site
[3].
Using the administrative database from the
National Insurance Agency, we selected all ﬁles sub-
mitted from January 1, 2002 and for which the pro-
cedure ended by December 31, 2004.
The impact of “evidence” on the reimbursement
decision was investigated indirectly by analyzing the
correlation between the decision and
1. the extent of the acquired evidence with the com-
pound: the assumption is that for the “limited
evidence group” (“class 1,” “class 2 new molecu-
lar entities [NMEs],” and “new indications”) the
extent of available evidence at submission is
often weaker than for line extensions of existing
medicines with well-known effectiveness and
safety. If evidence has an effect on the reimburse-
ment decision, a lower percentage of positive
decisions for the “limited evidence group” is
expected.
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2. the approval of the added value, for class 1 sub-
missions only: if added value is granted, evidence
must be proven by at least one positive active
control superiority trial. The assumption is: grant-
ing added value increases the probability for a
positive decision.
The reimbursement data are stored in MS Access
and analyzed by SPSS 12.0 for Windows (SPSS Inc.,
Chicago, IL). The analysis includes the calculation of
odds ratios (ORs) and the use of the Pearson chi-
squared test.
Results
The actual Belgian reimbursement process for nonge-
neric submissions yields in fact two distinct steps: ﬁrst
an evidence-based medicine (EBM) evaluation of the
therapeutic value of the medicinal product is done by
the reimbursement commission based on ﬁve deﬁned
criteria: efﬁcacy, safety, effectiveness, applicability, and
convenience. The result of the evaluation is binary:
either added (class 1) or similar (class 2) therapeutic
value. After advice provided by the reimbursement
commission, this evaluation is followed by the decision
taken by the Minister of Public Health and Social
Affairs to reimburse yes or no the submitted compound,
with or without speciﬁc reimbursement conditions.
In the period between 2002 and 2004, there were
1285 submissions for which a reimbursement decision
was taken: only the 824 nongeneric dossiers requiring
an evaluation of the therapeutic value are analyzed.
There were 159 requests for NMEs or 12.4% of all
handled submissions. Within the combined group of
NMEs, 42% (n = 67) were a request for class 1 or
added value medicine.
Whether “evidence” is a signiﬁcant factor affecting
the reimbursement decision, was investigated indi-
rectly by analyzing the correlation between the deci-
sion and
1. the extent of the acquired evidence with the com-
pound; and
2. the approval of the added value, for class 1 sub-
missions only.
The results of these two analyses are summarized in
Tables 1 and 2, respectively.
The percentage of positive decisions to reimburse
is signiﬁcantly lower for the limited (68.4%) as com-
pared to the extended (92.5%) evidence group
(Pearson chi-square = 76.8, P < 0.001). The ORs for a
negative decision decreased signiﬁcantly for submis-
sions with extended evidence: OR = 0.18 (0.12–0.27).
The approval of the added value-label is highly
predictive of a positive decision (90.6% vs. 51.4%,
Pearson chi-square = 12.26, P < 0.001, OR = 9.1 [2.3–
35.6]).
The median time to decision by the Minister is
175 days and is independent from the type of submis-
sion: nearly all decisions (90%) are taken within
180 days, but it takes about an additional 2 months
before the decision is really in application.
Discussion
Five deﬁned criteria are used for relative therapeutic
value evaluation. For the assessment of efﬁcacy and
safety, all International Conference on Harmonisation
Good Clinical Practice (ICH GCP) procedures adopted
by the EuropeanMedicines EvaluationAgency [4,5] are
applicable. The randomized controlled trial (RCT)
remains the golden standard for assessing the causal
relationship between treatment and outcome, minimiz-
Table 1 Cross-tabulation of the reimbursement decision and
the extent of evidence (further split by type of submission)
Extent of evidence
Reimbursement decision
Positive Negative Total
Limited evidence class 1 NME
n 47 20 67
Row % 70.1 29.9 100.0
Limited evidence class 2 NME
n 58 34 92
Row % 63.0 37.0 100.0
Limited evidence new indication
n 168 72 240
Row % 70.0 30.0 100.0
LIMITED EVIDENCE TOTAL
n 273 126 399
Row % 68.4 31.6 100.0
Extended evidence class 2 LE
n 183 1 184
Row % 99.5 0.5 100.0
Extended evidence other*
n 210 31 241
Row % 87.1 12.9 100.0
EXTENDED EVIDENCE TOTAL
n 393 32 425
Row % 92.5 7.5 100.0
TOTAL
n 666 158 824
Row % 80.8 19.2 100.0
*Other = parallel trade, price modiﬁcations, technical modiﬁcations, etc.
LE, line extension; NME, new molecular entity.
Table 2 Class 1 submissions only: cross tabulation of approval
of added value and reimbursement decision
Added therapeutic value
Yes No Total
Reimbursement decision
Positive
n 29 18 47
Column % 90.6 51.4 70.1
Negative
n 3 17 20
Column % 9.4 48.6 29.9
Total
n 32 35 67
Column % 100.0 100.0 100.0
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ing the possibility of bias [6]. For the assessment of
applicability (contraindications, special precautions),
the ofﬁcial information contained in the Summary of
Product Characteristics is used. Effectiveness and con-
venience for patient or physician relate to daily practice:
effectiveness cannot be predicted from efﬁcacy as cap-
tured in RCTs [6] mainly because the results from a
strict RCT study population may suffer from poor
generalizability to a broad daily practice population. In
the case of a positive decision, reimbursement may be
conditioned by specifying which physicians may pre-
scribe (e.g., only oncologists in hospital setting) and
which patients may beneﬁt (e.g., only patients at a
particular disease stage, exclusion of speciﬁc comorbid-
ity). This is often the case for the more expensive class 1
submission.
Over this 3-year period, 159 submissions (12.4% of
a total of 1285) relate to NMEs and 67 (42.1%) claim
added therapeutic value: this claim is approved in
47.8% of cases which means 20.1% of all submissions
for NME are ﬁnally considered as class 1 compound or
on average 11 compounds per year.
In France, the number of ﬁrst inscriptions for NME
submissions for which a quantitative rating of the
added therapeutic value was attributed in 2005 [7] was
108: only nine (8.3%) were rated as offering major or
important added value. The results are also similar to
the percentage of biotech medicines with superior
therapeutic value which has been estimated at 20% [8].
Clearly, the vast majority of NMEs do not offer
added therapeutic value.
The effect of “evidence” on the reimbursement deci-
sion has been investigated indirectly in this work.
In case of extended evidence, the odds for a negative
decision are signiﬁcantly reduced. From our work, it
appeared further that the approval of added value was
the strongest factor affecting the reimbursement deci-
sion: the odds for a negative decision increase signiﬁ-
cantly in case the added value claim is rejected. Class 1
submissions nearly always yield a higher price propo-
sition than existing comparators: if the added value
claim is rejected no price premium can be given.
Accordingly, price could not be used as confounder in
our study which shows that the new procedure facili-
tates the introduction to reimbursement of innovative
but more costly agents only if there is good evidence of
added therapeutic value.
Direct estimation of the level of evidence, using
widely accepted (ordinal) scales like the Scottish Inter-
collegiate Guidelines Network (SIGN) revised grading
system [9], was not systematically done for the dossiers
evaluated in this work: these scales focus merely on
evidence of efﬁcacy by attributing most weight to
RCTs and may not be appropriate when therapeutic
value also includes effectiveness besides efﬁcacy.
Before 2002, the mean time to a decision on reim-
bursement after registration was as high as 595 days
[10]. The introduction of the new procedure was asso-
ciated with a dramatic reduction of these timelines,
which are independent from the submission type and
are now in compliance with the European Directive.
Conclusion
The EU Transparency Directive on the use of objective
and veriﬁable criteria led to integration of EBM prin-
ciples in the reimbursement process of various EU
member states. In this article, we explored the impact
of evidence on the outcome of the reimbursement
procedure—the decision to approve or refuse reim-
bursement for a medicinal product—for all ﬁles
handled in the period 2002 to 2004.
Overall, the amount of product knowledge at sub-
mission and the clear demonstration of added thera-
peutic value are signiﬁcantly associated to the decision
taken: both factors suggest that evidence plays a role
in the decision-making process. The ﬁrst factor also
implies that regular review of reimbursed medicines is
needed as new data become available; the impact of
the factor “added therapeutic value” on the outcome
is a clear incentive to develop new effective drugs
addressing unmet or partially met medical needs.
Moreover, introducing evidence did not jeopardize the
respect of strict EU timelines.
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